Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Share-based Compensation (2016 - 2025)

Cytokinetics (CYTK) has disclosed Share-based Compensation for 15 consecutive years, with $40.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation changed N/A to $40.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $112.3 million for FY2025, 14.76% up from the prior year.
  • Share-based Compensation for Q4 2025 was $40.7 million at Cytokinetics, up from $30.7 million in the prior quarter.
  • The five-year high for Share-based Compensation was $40.7 million in Q4 2025, with the low at $5.3 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $19.2 million, with a median of $18.7 million recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 101.13% in 2022, then increased 8.96% in 2025.
  • Over 5 years, Share-based Compensation stood at $6.7 million in 2021, then surged by 101.13% to $13.5 million in 2022, then surged by 44.37% to $19.5 million in 2023, then skyrocketed by 30.12% to $25.4 million in 2024, then skyrocketed by 60.5% to $40.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $40.7 million, $30.7 million, and $27.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.